Edition:
United States

Profile: Allergan plc (AGN)

AGN on New York Consolidated

245.37USD
24 Feb 2017
Change (% chg)

$-0.96 (-0.39%)
Prev Close
$246.33
Open
$246.11
Day's High
$246.88
Day's Low
$243.95
Volume
1,842,944
Avg. Vol
4,687,499
52-wk High
$301.32
52-wk Low
$184.50

Allergan plc, incorporated on May 16, 2013, is a global pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. The Company is also is focused on developing, manufacturing and commercializing select over-the-counter (OTC) products. The Company’s segments include US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes branded products within the United States, including medical aesthetics, medical dermatology, eye care, neurosciences and urology therapeutic products. The US General Medicine segment includes branded products within the United States, including central nervous system, gastrointestinal, women’s health, anti-infectives and other brands. The International segment includes products sold outside the United States.

The Company markets a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. The Company is also engaged in regenerative medicines business. The Company offers a range of dermal matrix products. The Company’s products include Botox, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin, Estrace, Viibryd, Asacol, Minastrin 24, Aczone, Ozurdex, Carafate and Namenda IR.

Company Address

Allergan plc

Clonshaugh Business And Technolo
Coolock
DUBLIN     D17 E400
P: +35321.65235000

Company Web Links